Interpreting Efficacy Endpoints for BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Transitioning into a discussion of emerging clinical evidence, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine the efficacy endpoints that are most meaningful when evaluating BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM).

Dr. Mewawalla highlights the importance of progression-free survival (PFS) as a measure of both depth and durability of response, while also emphasizing the growing relevance of overall survival (OS) data as more effective therapies become available in earlier lines of treatment.

The discussion explores recently presented findings from the MajesTEC clinical program and how these data may inform treatment selection and sequencing decisions in patients with prior anti-CD38 exposure or refractory disease.

Additionally, the faculty review the role of response rates, complete response rates, and measurable residual disease (MRD) negativity as important indicators of treatment effectiveness.

The segment provides valuable insight into how clinicians interpret clinical trial outcomes and translate emerging evidence into everyday RRMM practice.